Please login to the form below

Not currently logged in

malaria drugs

This page shows the latest malaria drugs news and features for those working in and with pharma, biotech and healthcare.

FDA grants emergency authorisation to chloroquine for COVID-19

FDA grants emergency authorisation to chloroquine for COVID-19

Novartis and Bayer donate anti-malaria drugs to US stockpile. The US Food and Drug Administration (FDA) has approved the use of the decades old anti-malaria drugs hydroxychloroquine and chloroquine ... In a statement from the US Department of Health and

Latest news

  • Novartis: novel antimalarial is 'game-changing' Novartis: novel antimalarial is 'game-changing'

    Says cipargamin could be first new class of malaria drugs in 20 years. ... Novartis has published positive clinical data on what could become the first new class of antimalarial drugs since artemisinins were introduced 20 years ago.

  • Novartis compounds treat malaria in blood and liver

    In some patients, the malaria parasite can lie dormant in the liver for months or years, allowing the disease to re-establish itself later. ... use. Moreover, there is a critical need for new malaria drugs in the face of emerging resistance even to the

  • S-A agrees malaria research project

    Sanofi-aventis (S-A) and Medicines for Malaria Venture (MMV) have signed an agreement to research malaria treatments. ... MMV also signed a deal with AstraZeneca in June, 2010, to identify novel candidate drugs for the treatment of malaria, and worked

  • AZ and MMV join forces against malaria

    AstraZeneca (AZ) and Medicines for Malaria Venture (MMV) are to collaborate to identify novel candidate drugs for the treatment of malaria. ... Understanding and eliminating Indian malaria is one of the keys to eliminating malaria worldwide.".

  • R&D news in brief

    Malaria combination effective. The combination of the drugs artemether and lumefantrine are more effective than other drugs at treating malaria in young children, a UK study has found. ... The combination was tested in children with malaria aged between

More from news
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Interview: Charles Mgone, EDCTP Interview: Charles Mgone, EDCTP

    which are not normally carried out in the development of new drugs, where trials tend to be on general adult populations. ... EDCTP is working with many public-private partnership groups, including Medicines for Malaria Venture (MMV), with which it

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
The Creative Engagement Group

We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...